BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX) today announced that it has signed an exclusive development and supply agreement with Haemonetics Corporation (NYSE: HAE) for three premix products. Premix medications are ready to use intravenous drug products which eliminate compounding steps in the pharmacy or at the point of care.
